Acumen Pharmaceuticals, Inc
- Biotech or pharma, therapeutic R&D
Acumen Pharma is developing sabirnetug (ACU193), an antibody targeting amyloid beta oligomers and expects to release data from a 540 patient registration-quality Ph2 study in late 2026.
)
)
){kind=logo}
){kind=logo}
){kind=logo}